Literature DB >> 19557318

Predictors of pregnancy outcome in antiphospholipid syndrome: a review.

Sara De Carolis1, Angela Botta, Stefania Santucci, Serafina Garofalo, Carmelinda Martino, Alessandra Perrelli, Silvia Salvi, Sergio Ferrazzani, Leonardo Caforio, Giovanni Scambia.   

Abstract

In pregnant women, antiphospholipid syndrome (APS) is associated with an increased risk of preeclampsia, fetal intrauterine growth restriction, and other complications related to uteroplacental insufficiency. In the last two decades, several studies were performed to identify the predictive role of some parameters in relation to obstetric outcome in APS patients. Among these, the uterine velocimetry Doppler is the most studied. It provides a non-invasive method for the study of uteroplacental blood flow, being able to detect a condition of impaired placental perfusion, due to the presence of circulating antiphospholipid antibodies (aPL). To date, the uterine artery Doppler velocimetry resulted to be a useful tool to identify APS pregnancies at higher risk of adverse pregnancy outcome. False-positive IgM for toxoplasmosis, others, rubella, cytomegalovirus, herpes viruses (TORCH) complex is associated to a worse pregnancy outcome because it reflects a dysregulation of the immune system which may amplify placental autoimmune damage. Moreover low levels of complement components are related to an increased incidence of obstetrical complications, suggesting that placental deposition of immune complexes and activation of complement cascade may contribute to placental failure APS related. The abnormal uterine Doppler velocimetry, false-positive TORCH IgM and low levels of complement components can be considered prognostic indexes of poor pregnancy outcome in APS.

Entities:  

Mesh:

Year:  2010        PMID: 19557318     DOI: 10.1007/s12016-009-8144-z

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  48 in total

Review 1.  Systemic lupus erythematosus--is a viral aetiology a credible hypothesis?

Authors:  A M Denman
Journal:  J Infect       Date:  2000-05       Impact factor: 6.072

2.  Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo.

Authors:  S S Pierangeli; M Colden-Stanfield; X Liu; J H Barker; G L Anderson; E N Harris
Journal:  Circulation       Date:  1999-04-20       Impact factor: 29.690

3.  Clinical and laboratory aspects of raised virus antibody titres in systemic lupus erythematosus.

Authors:  N F Rothfield; A S Evans; J C Niederman
Journal:  Ann Rheum Dis       Date:  1973-05       Impact factor: 19.103

4.  Decidual vasculopathy and extensive placental infarction in a patient with repeated thromboembolic accidents, recurrent fetal loss, and a lupus anticoagulant.

Authors:  F De Wolf; L O Carreras; P Moerman; J Vermylen; A Van Assche; M Renaer
Journal:  Am J Obstet Gynecol       Date:  1982-04-01       Impact factor: 8.661

5.  Immunological abnormalities in primary APS evolving into SLE: 6 years follow-up in women with repeated pregnancy loss.

Authors:  J Carbone; M Orera; M Rodríguez-Mahou; C Rodríguez-Pérez; S Sánchez-Ramón; E Seoane; J J Rodríguez; J M Zabay; E Fernández-Cruz
Journal:  Lupus       Date:  1999       Impact factor: 2.911

6.  Anticardiolipin antibodies in patients with recurrent pregnancy wastage: treatment and uterine blood flow.

Authors:  Z Blumenfeld; Z Weiner; M Lorber; P Sujov; I Thaler
Journal:  Obstet Gynecol       Date:  1991-10       Impact factor: 7.661

Review 7.  Antiphospholipid syndrome and second- or third-trimester fetal death: follow-up in the next pregnancy.

Authors:  A-S Bats; V Lejeune; E Cynober; E Safar; M Gonzales; J Milliez; B Carbonne
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2004-06-15       Impact factor: 2.435

8.  Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep.

Authors:  Hong Zhou; Alisa S Wolberg; Robert A S Roubey
Journal:  Blood       Date:  2004-06-29       Impact factor: 22.113

9.  Activation of the alternative complement pathway accompanies disease flares in systemic lupus erythematosus during pregnancy.

Authors:  J P Buyon; J Tamerius; S Ordorica; B Young; S B Abramson
Journal:  Arthritis Rheum       Date:  1992-01

10.  Virus-specific IgG and IgM antibodies in normal and immunocompromised subjects infected with cytomegalovirus.

Authors:  L Rasmussen; D Kelsall; R Nelson; W Carney; M Hirsch; D Winston; J Preiksaitis; T C Merigan
Journal:  J Infect Dis       Date:  1982-02       Impact factor: 5.226

View more
  11 in total

1.  ApoE Receptor 2 Mediation of Trophoblast Dysfunction and Pregnancy Complications Induced by Antiphospholipid Antibodies in Mice.

Authors:  Jane E Salmon; Chieko Mineo; Victoria Ulrich; Shari E Gelber; Milena Vukelic; Anastasia Sacharidou; Joachim Herz; Rolf T Urbanus; Philip G de Groot; David R Natale; Anirudha Harihara; Patricia Redecha; Vikki M Abrahams; Philip W Shaul
Journal:  Arthritis Rheumatol       Date:  2016-03       Impact factor: 10.995

2.  Cutting-edge issues in organ-specific autoimmunity.

Authors:  M Eric Gershwin; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2011-10       Impact factor: 8.667

Review 3.  The autoimmune side of heart and lung diseases.

Authors:  Nancy Agmon-Levin; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2013-02       Impact factor: 8.667

4.  The use of uterine artery doppler as a predictive tool for adverse gestational outcomes in pregnant patients with autoimmune and thrombophilic disease.

Authors:  Roberta Capucci; Elena Pivato; Simona Carboni; Elena Mossuto; Gabriella Castellino; Melissa Padovan; Marcello Govoni; Roberto Marci; Alfredo Patella
Journal:  J Prenat Med       Date:  2011-04

5.  The future of autoimmunity.

Authors:  Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2012-04       Impact factor: 8.667

6.  What is the best time to assess the antiphospholipid antibodies (aPL) profile to better predict the obstetric outcome in antiphospholipid syndrome (APS) patients?

Authors:  Jose Omar Latino; Sebastián Udry; Silvia Perés Wingeyer; Diego Fernández Romero; Paula Micone; Gabriela de Larrañaga
Journal:  Immunol Res       Date:  2018-10       Impact factor: 2.829

Review 7.  Additional Treatments for High-Risk Obstetric Antiphospholipid Syndrome: a Comprehensive Review.

Authors:  Amelia Ruffatti; Ariela Hoxha; Maria Favaro; Marta Tonello; Anna Colpo; Umberto Cucchini; Alessandra Banzato; Vittorio Pengo
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

Review 8.  Obstetric Anti-phospholipid Syndrome: State of the Art.

Authors:  Maria Chiara Gerardi; Melissa Alexandre Fernandes; Angela Tincani; Laura Andreoli
Journal:  Curr Rheumatol Rep       Date:  2018-08-13       Impact factor: 4.592

9.  Identification of a Monoclonal Antibody That Attenuates Antiphospholipid Syndrome-Related Pregnancy Complications and Thrombosis.

Authors:  Chieko Mineo; Lane Lanier; Eunjeong Jung; Samarpita Sengupta; Victoria Ulrich; Anastasia Sacharidou; Cristina Tarango; Olutoye Osunbunmi; Yu-Min Shen; Jane E Salmon; Rolf A Brekken; Xianming Huang; Philip E Thorpe; Philip W Shaul
Journal:  PLoS One       Date:  2016-07-27       Impact factor: 3.240

10.  Risk Factors for Adverse Maternal and Fetal Outcomes in Women With Confirmed aPL Positivity: Results From a Multicenter Study of 283 Pregnancies.

Authors:  Micaela Fredi; Laura Andreoli; Elena Aggogeri; Elisa Bettiga; Maria Grazia Lazzaroni; Véronique Le Guern; Andrea Lojacono; Nathalie Morel; Jean Charles Piette; Sonia Zatti; Nathalie Costedoat-Chalumeau; Angela Tincani
Journal:  Front Immunol       Date:  2018-05-07       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.